-
TRUSTED AU LABORATORY
-
26 Mark Rd. Elizabeth South, SA - 5112
-
Same day delivery
Pull the syringe to:
(0.100ml)
This calculator is provided as a reference tool for research purposes only. Always follow your institution’s safety protocols when handling research compounds.
Cagrilintide 5mg is a research peptide studied in relation to amylin receptor signalling, metabolic pathway research, appetite regulation models and obesity-related research contexts.
Cagrilintide is commonly described as a long-acting amylin analogue. Amylin, also known as islet amyloid polypeptide, is a peptide hormone co-secreted with insulin by pancreatic beta cells and studied for its relationship with satiety, gastric emptying, glucagon regulation and metabolic signalling. In clinical research, cagrilintide has also been investigated in combination with semaglutide, a GLP-1 receptor agonist, under the development name CagriSema. A published Lancet study describes cagrilintide as a long-acting amylin analogue being investigated for weight management in combination with semaglutide.
This product is supplied for laboratory research use only. It is not a medicine, supplement, weight loss product, metabolic treatment, body composition product or injectable product for human use.
| Product Detail | Information |
|---|---|
| Product name | Cagrilintide |
| Common research names | AM833, long-acting amylin analogue |
| Size | 5mg |
| Product type | Research peptide |
| Research category | Metabolic Research |
| Common research interest | Amylin receptor signalling, satiety pathway research, metabolic pathway studies |
| Peptide type | Long-acting amylin analogue |
| Form | Lyophilised powder |
| Intended use | Laboratory research only |
| Human use | Not for human consumption, administration, weight loss or injection |
| Documentation | Certificate of Analysis should be checked before use |
| Component | Research Class | General Research Role |
| Cagrilintide | Long-acting amylin analogue | Studied in relation to amylin receptor and metabolic pathway research |
| Amylin analogue structure | Modified peptide based on amylin pathway research | Designed for research into satiety, glucagon and gastric-emptying signalling models |
| Acylated peptide design | Fatty-acid modified peptide format | Studied for extended activity and albumin-binding behaviour in research settings |
| Molecular formula | C194H312N54O59S2 | Listed in PubChem for Cagrilintide |
| CAS number | 1415456-99-3 | Common chemical registry identifier |
| Lyophilised peptide preparation | Freeze-dried peptide format | Supports stability before reconstitution when stored correctly |
PubChem lists Cagrilintide with the molecular formula C194H312N54O59S2 and CAS number 1415456-99-3. Product identity, purity and batch information should always be confirmed through supplier documentation and the Certificate of Analysis.
Cagrilintide is studied as a long-acting analogue of amylin. In metabolic research, amylin-related pathways are commonly examined because of their connection to appetite signalling, gastric-emptying models, glucagon regulation and body weight research.
A 2025 New England Journal of Medicine trial describes cagrilintide as a long-acting amylin analogue that binds the calcitonin receptor and all three amylin receptors. This receptor activity is part of why cagrilintide is often discussed in metabolic and obesity-related research.
Cagrilintide is also commonly studied in combination with semaglutide. This combination is referred to as CagriSema in clinical development. Current research literature should be treated as clinical research context only, not as a product claim for unapproved research-use cagrilintide vials.
| Research Area | Cagrilintide |
| Main research category | Metabolic peptide research |
| Parent pathway context | Amylin signalling |
| Common receptor interest | Amylin receptors and calcitonin receptor |
| Research pathway interest | Appetite signalling, glucagon regulation and gastric-emptying models |
| Combination research interest | Cagrilintide with semaglutide in CagriSema research |
| Evidence limitation | Clinical research context does not make research vials approved for human use |
| Product limitation | Research use only, not approved for human use |
| Feature | Cagrilintide | Semaglutide |
| Research class | Long-acting amylin analogue | GLP-1 receptor agonist |
| Main pathway | Amylin and calcitonin receptor pathway research | GLP-1 receptor pathway research |
| Common research interest | Appetite, satiety and metabolic pathway models | Incretin, glucose and appetite-related pathway models |
| Combination research | Studied together in CagriSema development | Studied together in CagriSema development |
| Product positioning | Research peptide only | Approved semaglutide medicines exist, but not equivalent to research-use products |
| Human-use claim | Not appropriate for this product | Only relevant to approved, regulated medicines |
| Common Online Claim | Safer Research-Use Wording |
| Weight loss | Studied in obesity-related clinical and metabolic research contexts |
| Appetite suppression | Studied in relation to amylin receptor and satiety pathway research |
| Fat loss | Better framed as metabolic and body-weight pathway research |
| GLP-1 alternative | Not accurate; cagrilintide is an amylin analogue, not a GLP-1 receptor agonist |
| CagriSema ingredient | Studied as part of cagrilintide and semaglutide combination research |
| Body transformation | Not an approved or appropriate product claim |
| Metabolic treatment | Not an approved or appropriate product claim |
Cagrilintide 5mg is not intended to diagnose, treat, cure or prevent any disease. It is not supplied for weight loss, appetite control, obesity treatment, fat loss, diabetes management, body transformation, bodybuilding, anti-ageing, metabolic health, performance enhancement or general wellness use.
All information on this page is provided for laboratory research and product handling context only.
There is no universal recommended dilution for Cagrilintide 5mg. Dilution depends on the research protocol, required working concentration, assay design, solvent compatibility, storage method and validated laboratory procedure.
For research concentration planning only, the basic formula is:
Total peptide amount divided by diluent volume equals final concentration.
| Diluent Added to 5mg Vial | Final Concentration |
| 0.5mL | 10mg/mL |
| 1mL | 5mg/mL |
| 2mL | 2.5mg/mL |
| 2.5mL | 2mg/mL |
| 5mL | 1mg/mL |
| 10mL | 0.5mg/mL |
These are research concentration examples only. They are not human dosing instructions and must not be used to calculate injection quantities.
Before handling Cagrilintide 5mg in a laboratory setting, make sure all materials, documentation and clean handling conditions are prepared.
| Item | Purpose |
| Product vial | Contains lyophilised Cagrilintide peptide |
| Certificate of Analysis | Confirms batch-level testing information |
| Suitable research-grade diluent | Used to prepare a working research solution |
| Sterile lab consumables | Helps reduce contamination risk |
| Personal protective equipment | Gloves, lab coat and eye protection |
| Alcohol wipes or approved disinfectant | Used for surface and vial-top preparation |
| Laboratory labels | Records concentration, date, batch and handler details |
| Cold storage access | Supports correct storage after preparation |
| Disposal container | Used for compliant laboratory waste disposal |
The following is a general laboratory handling framework only. Always follow the product Certificate of Analysis, supplier documentation, SDS, institutional procedures and validated research protocol.
Check the product label, batch number, Certificate of Analysis and storage requirements before handling the vial.
Use a clean laboratory workspace. Wear appropriate PPE and disinfect the bench surface, vial top and any required equipment.
If the vial has been stored cold, allow it to equilibrate according to laboratory procedure before opening or reconstitution. Avoid condensation entering the vial.
Add the selected research-grade diluent slowly down the inside wall of the vial. Avoid forceful spraying directly onto the lyophilised powder.
Gently swirl or roll the vial until the powder is dissolved. Avoid aggressive shaking, unnecessary vortexing or foaming unless a validated protocol specifically allows it.
Check the solution for cloudiness, visible particles, unusual colour changes or undissolved material. If anything appears abnormal, quarantine the vial and check supplier documentation.
Label the vial or aliquots with the product name, concentration, diluent used, date prepared, batch number and researcher initials.
Place the reconstituted solution into the required storage condition as soon as possible. Avoid unnecessary warming, cooling or repeated freeze-thaw cycles.
Some lyophilised peptide products may take time to fully hydrate. Dissolution should always be handled gently and according to laboratory protocol.
| Issue | What It May Indicate | Safer Response |
| Powder clinging to vial wall | Static or lyophilisation residue | Allow more contact time with diluent |
| Small particles remain | Incomplete hydration | Continue gentle swirling |
| Cloudy solution | Possible incompatibility or contamination | Stop and check documentation |
| Foaming | Too much agitation | Let the solution settle and avoid shaking |
| Colour change | Possible degradation or contamination | Do not continue without supplier guidance |
| Storage Factor | Guidance |
| Product form | Lyophilised powder |
| Storage condition | Follow supplier label and Certificate of Analysis |
| Light exposure | Protect from unnecessary light exposure |
| Moisture exposure | Keep sealed until use |
| Temperature changes | Avoid repeated temperature cycling |
| Handling | Minimise unnecessary opening or vial puncture |
| Storage Factor | Guidance |
| Storage condition | Follow validated research protocol |
| Labelling | Record concentration, date, diluent and batch number |
| Freeze-thaw cycles | Avoid repeated freeze-thaw exposure |
| Aliquoting | Use small research aliquots where appropriate |
| Contamination control | Use clean laboratory technique |
| Light exposure | Protect from unnecessary light exposure where required |
| Disposal | Dispose according to laboratory waste procedures |
Peptides may be sensitive to temperature, light, pH, agitation and contamination. Storage conditions should be confirmed through supplier documentation or the laboratory’s validated method.
This page does not provide human dosing, injection instructions, injection schedules or administration guidance.
Cagrilintide 5mg is not supplied for human or animal administration. It is a laboratory research-use product only.
For research settings, any measured aliquots should be prepared according to the concentration required by the approved research protocol. All calculations should be checked, documented and traceable.
| Planning Item | What to Record |
| Final concentration | Total peptide amount and diluent volume |
| Working solution | Concentration used in the research protocol |
| Aliquot volume | Volume transferred into each labelled lab tube |
| Batch details | Product batch, CoA and preparation date |
| Storage location | Fridge, freezer or other controlled storage area |
| Handler details | Researcher name or initials |
| Preparation date | Date and time of reconstitution |
| Disposal date | When the aliquot should no longer be used |
Correct handling is important for research consistency, contamination control and product traceability. Most mistakes occur when products are not labelled clearly, concentration calculations are not recorded or storage conditions are not followed.
Because cagrilintide is commonly discussed online in relation to weight management and CagriSema, product pages should avoid wording that could be interpreted as encouraging human weight loss, appetite suppression, self-injection or obesity treatment use.
| Always | Why It Matters |
| Check the Certificate of Analysis | Confirms batch-level information |
| Use PPE | Reduces contamination and exposure risk |
| Label every vial and aliquot | Prevents mix-ups |
| Record concentration calculations | Supports traceability |
| Use clean laboratory technique | Reduces contamination risk |
| Follow institutional protocols | Keeps handling consistent and auditable |
| Store according to documentation | Helps protect peptide integrity |
| Dispose of lab waste correctly | Supports safety and compliance |
| Use research-use wording only | Reduces misleading human-use interpretation |
| Never | Why It Is Risky |
| Never use for self-injection | Product is research use only |
| Never sell or promote as a weight loss product | Creates human-use and compliance risk |
| Never make appetite suppression claims | Not an approved or appropriate product claim |
| Never describe it as Ozempic, Wegovy or GLP-1 | Misleading because cagrilintide is an amylin analogue |
| Never compare it directly to approved obesity medicines | Misleading and clinically inappropriate |
| Never make diabetes treatment claims | Not an approved or appropriate product claim |
| Never assume purity without CoA | Batch quality must be documented |
| Never use a damaged or unlabelled vial | Identity and sterility may be uncertain |
| Never shake aggressively | May affect peptide integrity |
| Never use random solvents | May damage the peptide or alter research results |
| Never leave reconstituted product unlabelled | Creates traceability risk |
| Never rely on social media protocols | They may be inaccurate, unsafe or non-compliant |
The table below is for concentration planning only. It does not represent dosage, injection quantity or recommended administration.
| Total Vial Amount | Diluent Volume | Final Concentration |
| 5mg | 0.5mL | 10mg/mL |
| 5mg | 1mL | 5mg/mL |
| 5mg | 2mL | 2.5mg/mL |
| 5mg | 2.5mL | 2mg/mL |
| 5mg | 5mL | 1mg/mL |
| 5mg | 10mL | 0.5mg/mL |
If a researcher adds 1mL of suitable research-grade diluent to a 5mg vial, the resulting concentration is 5mg/mL.
This calculation is for research concentration planning only. It is not a human or animal dosing example.
Cagrilintide is a long-acting amylin analogue studied in metabolic research, satiety pathway research, amylin receptor signalling and obesity-related clinical research contexts.
No. Cagrilintide is not a GLP-1 receptor agonist. It is commonly described as an amylin analogue. It may be studied with semaglutide, but the two compounds belong to different research classes.
CagriSema is the development name commonly used for the combination of cagrilintide and semaglutide in clinical research. A research-use cagrilintide vial is not equivalent to an approved fixed-dose medicine.
This research product is not approved or supplied for weight loss, obesity treatment, appetite control or human use. It should be described only as a laboratory research product.
Cagrilintide is studied because the amylin pathway is connected to appetite, satiety, gastric-emptying and glucagon-related research models.
A Certificate of Analysis provides batch-level testing information. It helps researchers verify product identity, purity and quality documentation before use in a research setting.
| Resource | Why It Is Useful |
| PubChem Cagrilintide compound profile | Useful background on Cagrilintide identity, molecular formula and CAS number. |
| Lancet cagrilintide and semaglutide study | Useful background on cagrilintide as a long-acting amylin analogue studied with semaglutide. |
| New England Journal of Medicine CagriSema research | Useful background on cagrilintide and semaglutide clinical research context. |
Cagrilintide 5mg for qualified laboratory research only. Not for human or veterinary use.
